Regeneron COVID-19 antibody cocktail helps prevent symptomatic disease in study
April 13 2021, 08:00
A monoclonal antibody cocktail developed by Regeneron and Roche dropped the risk of symptomatic COVID-19 by up to 76% after three days for recently infected individuals not yet experiencing symptoms, according to a press release posted Monday.
A monoclonal antibody cocktail developed by Regeneron and Roche dropped the risk of symptomatic COVID-19 by up to 76% after three days for recently infected individuals not yet experiencing symptoms, according to a press release posted Monday.
Source:
FOX News